mRNA-4157 (V940) in combination with KEYTRUDA reduced the risk of recurrence or death by 44% compared to KEYTRUDA alone in stage III/IV melanoma patients
The new team members, Solenn Percelay and Noémie Spinelli, will support the organization’s commitment to excellence in humanized mouse model care and use
Clinical Decision Support Systems' huge potential to help ensure that each patient can receive high-quality care; study shows a reduction in diagnostic errors from 24% to 2%
Acceptance based on results from the Phase 3 KEYNOTE-859 trial, which showed significant overall survival benefit in these patients with HER2-negative disease, regardless of PD-L1 expression
Enabling wireless monitoring In ambulances and homes
The session took place in the presence of Union Ministers Hardeep Singh Puri and Gen V K Singh along with Anil Agarwal, Rajya Sabha Member of Parliament
To enable company to be future-ready by tapping potential in CDMO space
The Award acknowledges Emcure's contribution in the field of HIV/AIDS to improve the quality of life of people living with HIV/AIDS.
Microsoft Cloud for Healthcare and Cognizant’s TriZetto healthcare products aim to enhance transparency for consumers and increase interoperability for providers and payers
Designation based on positive data from Phase 2b KEYNOTE-942/mRNA-4157-P201 trial and unmet need for additional therapeutic options for certain types of melanoma
Subscribe To Our Newsletter & Stay Updated
